Table A1.
PD-L1 and PD-L2 Genetic and IHC Analysis
| Diagnosis | Genetic Analysis | IHC | ||||
|---|---|---|---|---|---|---|
| Polysomy | Gain | Amplification | Translocation | Tumor PD-L1 (%, Int) | Tumor PD-L2 (%, Int) | |
| B-cell lymphoma (n = 20) | ||||||
| DLBCL (n = 6) | ||||||
| DLBCL #1 | + | – | – | – | –* | – |
| DLBCL #2 | + | – | – | – | – | – |
| DLBCL #3 | – | – | – | – | – | – |
| DLBCL #4 | – | – | – | – | – | – |
| DLBCL #5 | – | – | – | – | – | – |
| DLBCL #6 | – | – | – | – | – | – |
| FL (n = 6) | ||||||
| FL #1 | – | – | – | – | – | – |
| FL #2† | – | – | – | – | – | – |
| FL #3 | – | – | – | – | – | – |
| FL #4† | – | – | – | – | – | – |
| FL #5 | – | – | – | – | – | – |
| FL #6 | – | – | – | – | NA | NA |
| Other B-cell lymphoma (n = 8) | ||||||
| MCL #1 | – | – | – | – | 5%, 3+ | – |
| MCL #2 | – | – | – | – | – | – |
| MCL #3 | – | – | – | – | – | – |
| MCL #4 | – | – | – | – | – | – |
| MZL | – | – | – | – | – | – |
| SLL #1 | – | – | – | – | – | – |
| SLL #2 | – | – | – | – | – | NA |
| B-cell NOS | – | – | – | – | – | 20%, 2+ (c) |
| T-cell lymphoma (n = 8) | ||||||
| MF (n = 4) | ||||||
| MF #1 | + | – | – | + | – | 70%, 3+ (m) |
| MF #2 | – | – | – | – | 20%, 2+ | – |
| MF #3 | – | – | – | – | – | – |
| MF #4 | – | – | – | – | – | – |
| PTCL (n = 3) | ||||||
| PTCL #1 | – | – | – | – | – | – |
| PTCL #2 | – | – | – | – | – | – |
| PTCL #3 | – | – | – | – | – | – |
| Other T-cell lymphoma (n = 1) | ||||||
| Other #1 | – | – | – | – | – | – |
NOTE. Previously published criteria for the genetic (Ansell et al8) and PD-L1 IHC (Chen et al1) analyses were used. Tumor cells needed to exhibit 2+ or 3+ membrane staining (Int) in ≥ 5% of malignant cells to be considered positive for PD-L1. For PD-L2, 2+ to 3+ cytoplasmic or membrane staining in ≥ 5% of malignant cells was termed positive. Abbreviations: c, cytoplasmic staining; DLBCL, diffuse large B-cell lymphoma; FL, follicular lymphoma; IHC, immunohistochemical; Int, intensity; m, membrane staining; MCL, mantle cell lymphoma; MF, mycosis fungoides; MZL, marginal zone lymphoma; NA, not available; NOS, not otherwise specified; PD-L1, programmed death ligand 1; PD-L2, programmed death ligand 2; PTCL, peripheral T-cell lymphoma; SLL, small lymphocytic lymphoma.
Two percent of malignant cells exhibited 2+ membrane PD-L1 staining.
In FL #2 and FL #4, 40% of nonmalignant cells were PD-L1 positive.